10a.2
Cannabis vs. Isolated THC
cannabis flower
high-THC concentrates (dabs)
CBD-balanced strains
synthetic cannabinoids (K2/Spice)
Cannabis is the most-studied orchestral drug in modern pharmacology. The plant contains over 400 distinct compounds, of which roughly 100 are cannabinoids (Russo, 2011). Module 7d focused on THC because it is the dominant psychoactive. But "cannabis" and "THC" are not synonymous.
The Main Players
Lead molecule
THC (Δ9-tetrahydrocannabinol)
Partial agonist at CB1 — as described in Module 7d. Produces euphoria, hippocampal memory suppression, amygdala anxiety modulation.
Key modulator
CBD (cannabidiol)
Present in significant amounts in many strains (sometimes >10%). Does not bind CB1 directly with significant affinity. Instead acts as a negative allosteric modulator of CB1 — changes the receptor's shape so that THC binds with less potency (Laprairie et al., 2015). Also inhibits FAAH, the enzyme that breaks down anandamide, raising endogenous cannabinoid tone. Has anti-anxiety, antipsychotic, and anti-seizure effects in clinical studies.
Minor cannabinoids
CBG, CBN, CBC
CBN appears mildly sedative, especially after THC oxidation in aged cannabis. Their full pharmacology is still being characterized.
Modulators
Terpenes — myrcene, limonene, pinene, linalool, β-caryophyllene
Volatile aromatic compounds — the "smell" of different strains. Some have independent psychoactive effects: linalool binds GABA-A weakly, β-caryophyllene binds CB2 directly, pinene inhibits acetylcholinesterase. Likely modulate blood-brain barrier penetration and metabolism of cannabinoids (Russo, 2011).
The Mechanism of the Entourage
CBD's effect on THC is the cleanest example:
THC only (concentrate / dab)
- THC binds CB1 at full potency
- Amygdala CB1 unmodulated → U-shaped anxiety curve tips into paranoia at high doses
- Hippocampal CB1 unmodulated → maximal memory disruption
- Cortical glutamate suppression unmodulated → cognitive impairment, psychosis risk in vulnerable users
THC + CBD (balanced whole-plant)
- CBD allosterically reduces THC binding at CB1 (Laprairie et al., 2015)
- Subjective intoxication less intense for the same THC dose
- Anxiety and paranoia reduced (Englund et al., 2013)
- Memory disruption reduced
- Psychotomimetic effects reduced (Morgan et al., 2010)
Modern Cannabis vs. Past Cannabis
The cannabis supply has shifted dramatically over the past 30 years — away from balanced whole-plant chemistry, toward near-isolated THC:
1990s street cannabis
3–5%
THC · near 1:1 THC:CBD
Significant CBD content. The "entourage" was intact. Studies from this era describe a different drug than what's sold today.
2020s commercial cannabis
20–30%
THC · CBD bred near-zero
CBD content reduced to near-zero by selective breeding for potency (ElSohly et al., 2016). The modulator has been largely removed.
Concentrates / dabs / vape carts
70–95%
THC · minimal CBD, reduced terpenes
Much closer to isolated THC than whole-plant cannabis. CBD and terpene content varies by extraction method — live resin and rosin retain more terpenes than distillate — but all are a fraction of what's in flower. The orchestra is significantly stripped down.
This may explain why:
- Cannabis-induced psychosis incidence has risen alongside potency (Di Forti et al., 2019)
- Cannabinoid hyperemesis syndrome has emerged as a clinical entity only in the past two decades
- Adolescent cannabis use is associated with measurably greater cortical-maturation effects in the high-THC era than in older studies (Volkow et al., 2014)
Synthetic Cannabinoids — The Most Extreme Case
K2, Spice, "Mojo," "Black Mamba" are full agonists at CB1 with no CBD, no terpenes, no entourage.
Same receptor as THC, no orchestra, qualitatively different and more dangerous: seizures, severe psychosis, acute kidney injury, deaths (Tai & Fantegrossi, 2014). This is the orchestral principle at its endpoint — maximum lead, zero support.